ORXOY实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 22:02):

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom...

Stats
今日成交量	655.00
平均成交量	67.00
市值	48.23M
EPS	$-0.967 ( 2023-09-30 )
下一个收益日期	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.12
ATR14	$0 (0.00%)

Orexo AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Orexo AB (publ) 财务报表

Annual	2023
营收:	$638.80M
毛利润:	$472.80M (74.01 %)
EPS:	$-3.73

FY	2023
营收:	$638.80M
毛利润:	$472.80M (74.01 %)
EPS:	$-3.73

FY	2022
营收:	$624.30M
毛利润:	$521.70M (83.57 %)
EPS:	$-5.17

FY	2021
营收:	$565.00M
毛利润:	$486.10M (86.04 %)
EPS:	$-2.13

Financial Reports:

No articles found.

Orexo AB (publ)

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

实时更新： Orexo AB (publ) [ORXOY]

Upcoming Earnings Alert